2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5533 Treatment-free remission following complete molecular response with ropeginterferon alfa-2b in patients with polycythemia vera

Jian Huang, MD, PhD, Rongfeng Fu2, Albert Qin, MD PhD3, Zonghong Shao, MD4, Jie Bai, MD5, Hu Zhou, MD6, Na Xu7, Suning Chen8, Xue Lan Zuo9, Xin Du, MD10, Minghui Duan, MD11, Li Wang12, Pei Li13, Xuhan Zhang14, Sujiang Zhang, MD15, Daoxiang Wu16, Jingjing Zhang17, Weihong Shen, MS, MBA18, William Wang, MD19, Lei Zhang, MD20, Zhijian Xiao21, Jie Jin, MD22
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 Medical Research & Clinical Operations, PharmaEssentia Corporation, Taiwan, China
4 Department of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China
5 Department of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China
6 The Affiliated Cancer Hospital of Zhengzhou University & HenanCancer Hospital, Hemostasis and Thrombosis Diagnostic Engineering Research Center of HenanProvince, Zhengzhou, Henan, China
7 Nanfang Hospital, Southern Medical University, Guangzhou, China
8 Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China
9 Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China
10 Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
11 Department of Hematology, Peking Union Medical College Hospital, Beijing, China
12 The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
13 Huashan Hospital of Fudan University, Shanghai, China
14 Department of hematology,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
15 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
16 PharmaEssentia Biotech (Beijing) Limited, Beijing, China
17 PharmaEssentia Biotech (Beijing) Limited, Beijing, China
18 PharmaEssentia Biotech (Beijing) Limited, Beijing, China
19 PharmaEssentia Biotech (Beijing) Limited, Beijing, China
20 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
21 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
22 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Polycythemia vera (PV) is a subtype of Philadelphia-negative myeloproliferative neoplasm (MPN) with most cases harboring the acquired mutation JAK2V617F. It is characterized by persistent erythrocytosis and elevated risks of thrombosis and progression to myelofibrosis and acute leukemia. It is a chronic disease often requiring long-term, continuous treatment. Non-specific cytoreductive treatment such as the commonly used hydroxyurea can maintain hematologic control and reduce thrombotic risk, but lacks any disease-modifying, anti-clonal effect. Ropeginterferon alfa-2b is a next generation interferon-based therapy which induces complete hematologic response (CHR) and reduces the allele burden, or variant allele frequency (VAF) of JAK2V617F in PV. Previously we have shown that ropeginterferon alfa-2b treatment led to a high rate of complete molecular response (CMR) at 3 years under a higher-initial dose and accelerated titration (HIDAT) dosing regimen in PV. CMR potentially reflects effective suppression of JAK2V617F-carrying neoplastic cells and a durable CMR may suggest the effective depletion of mutant clones, leading to sustained remission even after treatment discontinuation. Here, we investigated whether there is a correlation between durable CMR and prolonged treatment-free remission (TFR) in an ongoing phase II extension study in PV.

Following the initial 12-month (1-year) treatment, 44 patients entered the extension study phase and 40 completed 48 months (4 years) of ropeginterferon alfa-2b therapy. CHR was maintained over long-term follow-up, with CHR rates of 68.2% (30/44), 72.7% (32/44), 70.5% (31/44), and 65.9% (29/44) at months 39, 42, 45, and 48, respectively. Median JAK2V617F VAF decreased from 61.2% at baseline to 4.0% at month-48. Molecular response as defined by the European LeukemiaNet 2009 criteria was observed in 34 patients of 40 (85.0%) at month-48 based on the available case analysis, including CMR in 15 of 40 (37.5%), assessed by Next-Generation Sequencing (NGS) with a lower limit of quantitation (LLOQ) of 1%. Patients with sustained CHR and CMR for 2 years were eligible for enrollment into an exploratory TFR study. To date, 8 patients have initiated treatment-free observation, with the longest TFR duration reaching 16 months. Among patients with NGS-defined CMR, droplet digital PCR with an LLOQ of 0.02% was further used to measure JAK2V617F VAF. For the 8 patients under TFR assessment, undetectable JAK2V617F VAF was observed in 2 patients, while additional 3 and 3 patients had residual JAK2V617F VAFs of 0.02–0.1% and 0.1 – 0.2%, respectively, consistent with very low-level residual molecular evidence of disease.

Long-term treatment with ropeginterferon alfa-2b was well-tolerated, with no grade 4 or higher adverse events (AEs) observed in the 4-year study. White blood cell count decreased, neutrophil count decreased, alanine aminotransferase increased, and gamma-glutamyltransferase increased were the most common AEs. The events were clinically manageable and did not result in meaningful clinical sequelae. No progression to secondary myelofibrosis or acute myeloid leukemia was observed during the study. Thrombo-hemorrhagic complications occurred in 1 patient.

In conclusion, sustained CMR achieved with ropeginterferon alfa-2b treatment enabled exploration of TFR in selected patients with PV. The data support further prospective evaluation of TFR after CMR. Further assessment to analyze how many of the TFR patients have remained in TFR and/or experienced hematologic or molecular relapse is ongoing.

 

Jian Huang, MD, PhD: No relevant conflicts of interest to declare.